Denmark
-
Danish firm specialised in treatment for metabolic diseases issues 6.5m shares -
Vaccine maker issued shares in oversubscribed deal to fund acquisition
-
Sizeable euro funding to supplement domestic deals across the Nordic region as Swedish domestic advantage ebbs
-
Sovereign to balance diversification with domestic programme
-
Sterling primary supply also continued with EIB
-
The Italian lender managed to score size with a slim 10bp-15bp new issue premium
-
The sovereign will be able to price within where it might in dollars
-
Lower reset spreads on outstanding debt weigh on Danish firm’s curve
-
Dealmaking veteran says people "you know and love" were a key factor for the decision
-
Long and short deals from MuHyp and Sparebank 1 had smoother execution
-
Widening in local currency benchmark covered bonds makes new domestic issuance unattractive
-
Meeting MREL targets and topping up on subordinated debt issuance to drive the largest Nordic banks' funding plans
